- Home
- Publications
- Publication Search
- Publication Details
Title
The Role of mTOR Signaling as a Therapeutic Target in Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 4, Pages 1743
Publisher
MDPI AG
Online
2021-02-10
DOI
10.3390/ijms22041743
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of resistance to mTOR inhibitors
- (2020) Luigi Formisano et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- mTOR at the nexus of nutrition, growth, ageing and disease
- (2020) Grace Y. Liu et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma
- (2020) Kazuki Kuroshima et al. CANCER SCIENCE
- Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease
- (2020) Daehong Kim et al. Nature Communications
- Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity
- (2020) Federico La Manna et al. Frontiers in Oncology
- Regulation of mTORC2 Signaling
- (2020) Wenxiang Fu et al. Genes
- Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis
- (2020) Ying Chen et al. Frontiers in Cell and Developmental Biology
- Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide
- (2020) Andres Vargas-Toscano et al. Cancers
- Targeting PI3K in cancer: mechanisms and advances in clinical trials
- (2019) Jing Yang et al. Molecular Cancer
- Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
- (2019) Ying Zhang et al. Expert Opinion on Drug Metabolism & Toxicology
- mTOR: Role in cancer, metastasis and drug resistance
- (2019) Avaniyapuram Kannan Murugan SEMINARS IN CANCER BIOLOGY
- Cryo-EM structure of human mTOR complex 2
- (2018) Xizi Chen et al. CELL RESEARCH
- PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy
- (2018) Nahal Haddadi et al. Molecular Cancer
- Targeting the PI3K pathway in cancer: are we making headway?
- (2018) Filip Janku et al. Nature Reviews Clinical Oncology
- The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma
- (2018) Ning Wu et al. TECHNOLOGY IN CANCER RESEARCH & TREATMENT
- Architecture of the human mTORC2 core complex
- (2018) Edward Stuttfeld et al. eLife
- Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas
- (2017) Chengfeng Bi et al. HAEMATOLOGICA
- Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non–Small Cell Lung Cancer
- (2017) Emily Castellanos et al. Journal of Thoracic Oncology
- Maximising the potential of AKT inhibitors as anti-cancer treatments
- (2017) Jessica S. Brown et al. PHARMACOLOGY & THERAPEUTICS
- Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma
- (2017) Elisa Oricchio et al. Science Translational Medicine
- p-Akt as a potential poor prognostic factor for gastric cancer: a systematic review and meta-analysis
- (2017) Fang Cao et al. Oncotarget
- Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas
- (2017) Chengfeng Bi et al. HAEMATOLOGICA
- Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy
- (2017) Wennan Zhao et al. Acta Pharmaceutica Sinica B
- Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis
- (2016) Shuangjiang Li et al. BMC CANCER
- The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
- (2016) Jennifer L. Hsu et al. CANCER AND METASTASIS REVIEWS
- Regulation of mTORC1 by growth factors, energy status, amino acids and mechanical stimuli at a glance
- (2016) Peter Bond Journal of the International Society of Sports Nutrition
- The Enigma of Rapamycin Dosage
- (2016) S. Mukhopadhyay et al. MOLECULAR CANCER THERAPEUTICS
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis
- (2016) Maria L. Mancini et al. Oncotarget
- 5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells
- (2015) Suman Mukhopadhyay et al. CELL CYCLE
- mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR
- (2015) Yancun Yin et al. CELL RESEARCH
- Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
- (2015) C. P. Hall et al. CLINICAL CANCER RESEARCH
- Reciprocal Regulation of AMP-activated Protein Kinase and Phospholipase D
- (2015) Suman Mukhopadhyay et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Regulation of mTORC1 by PI3K signaling
- (2015) Christian C. Dibble et al. TRENDS IN CELL BIOLOGY
- The prognostic value of phosphorylated Akt in breast cancer: a systematic review
- (2015) Zu-Yao Yang et al. Scientific Reports
- Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance
- (2015) Kimmo J. Hatanpaa et al. NEOPLASIA
- PTEN
- (2014) Carolyn A. Worby et al. Annual Review of Biochemistry
- PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
- (2014) HaiXia Li et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- Spatial Control of the TSC Complex Integrates Insulin and Nutrient Regulation of mTORC1 at the Lysosome
- (2014) Suchithra Menon et al. CELL
- Prognostic value of phospho-Akt in patients with non-small cell lung carcinoma: A meta-analysis
- (2014) Yang Yang et al. INTERNATIONAL JOURNAL OF CANCER
- Harnessing Allostery: A Novel Approach to Drug Discovery
- (2014) Shaoyong Lu et al. MEDICINAL RESEARCH REVIEWS
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- The Role of the PTEN/PI3K/Akt Pathway on Prognosis in Epithelial Ovarian Cancer: A Meta-Analysis
- (2014) J. Cai et al. ONCOLOGIST
- Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1
- (2014) Sharmila Mallya et al. PLoS One
- A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
- (2014) B. C. Grabiner et al. Cancer Discovery
- Gain of Interaction with IRS1 by p110α-Helical Domain Mutants Is Crucial for Their Oncogenic Functions
- (2013) Yujun Hao et al. CANCER CELL
- Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma
- (2013) Florian Ewald et al. INTERNATIONAL JOURNAL OF CANCER
- mTOR kinase structure, mechanism and regulation
- (2013) Haijuan Yang et al. NATURE
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis
- (2013) Pengda Liu et al. NATURE CELL BIOLOGY
- The Prognostic Value of Phosphorylated AKT Expression in Non-Small Cell Lung Cancer: A Meta-Analysis
- (2013) Zhi-Xin Qiu et al. PLoS One
- Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer
- (2013) L-Y Huw et al. Oncogenesis
- Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
- (2012) Nicole Grabinski et al. Molecular Cancer
- TBC1D7 Is a Third Subunit of the TSC1-TSC2 Complex Upstream of mTORC1
- (2012) Christian C. Dibble et al. MOLECULAR CELL
- The translational landscape of mTOR signalling steers cancer initiation and metastasis
- (2012) Andrew C. Hsieh et al. NATURE
- AMPK: a nutrient and energy sensor that maintains energy homeostasis
- (2012) D. Grahame Hardie et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
- (2012) D. W. Lamming et al. SCIENCE
- Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney
- (2011) Laura R. Pearce et al. BIOCHEMICAL JOURNAL
- The mTOR (Mammalian Target of Rapamycin) Kinase Maintains Integrity of mTOR Complex 2
- (2011) Chien-Hung Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases
- (2011) Oscar Vadas et al. Science Signaling
- Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E
- (2010) Andrew C. Hsieh et al. CANCER CELL
- Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic
- (2010) P. Workman et al. CANCER RESEARCH
- Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids
- (2010) Yasemin Sancak et al. CELL
- MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC)
- (2010) Ji-guang Zhang et al. CLINICA CHIMICA ACTA
- Requirement of the mTOR Kinase for the Regulation of Maf1 Phosphorylation and Control of RNA Polymerase III-dependent Transcription in Cancer Cells
- (2010) Boris Shor et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- mTORC1 Directly Phosphorylates and Regulates Human MAF1
- (2010) A. A. Michels et al. MOLECULAR AND CELLULAR BIOLOGY
- Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
- (2010) T Sato et al. ONCOGENE
- Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
- (2010) Wen-I Wu et al. PLoS One
- Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers
- (2010) C. G. Fedele et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Differential Enhancement of Breast Cancer Cell Motility and Metastasis by Helical and Kinase Domain Mutations of Class IA Phosphoinositide 3-Kinase
- (2009) H. Pang et al. CANCER RESEARCH
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
- (2009) Timothy R. Peterson et al. CELL
- The nuts and bolts of AGC protein kinases
- (2009) Laura R. Pearce et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Common corruption of the mTOR signaling network in human tumors
- (2009) S Menon et al. ONCOGENE
- Molecular Mechanism of an Oncogenic Mutation That Alters Membrane Targeting: Glu17Lys Modifies the PIP Lipid Specificity of the AKT1 PH Domain†
- (2008) Kyle E. Landgraf et al. BIOCHEMISTRY
- mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
- (2008) C Le Tourneau et al. BRITISH JOURNAL OF CANCER
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
- (2008) Dana M. Gwinn et al. MOLECULAR CELL
- Regulation of TORC1 by Rag GTPases in nutrient response
- (2008) Eunjung Kim et al. NATURE CELL BIOLOGY
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- AKT1 E17K in human solid tumours
- (2008) F E Bleeker et al. ONCOGENE
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
- (2008) A. Y. Choo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
- (2008) Y. Sancak et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started